Nisa Investment Advisors’s Spyre Therapeutics SYRE Stock Holding History

Nisa Investment Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Buy	2,347 +431	+22%	+$31.5K	﹤0.01%	1231
2026 Q1	$96.6K	Buy	1,916 +1,211	+172%	+$45.7K	﹤0.01%	1436
2025 Q4	$23.1K	Hold	705	–	–	﹤0.01%	1886
2025 Q3	$11.8K	Buy	705 +159	+29%	+$2.59K	﹤0.01%	2215
2025 Q2	$8.17K	Buy	546 +362	+197%	+$5.36K	﹤0.01%	2340
2025 Q1	$2.97K	Buy	184 +64	+53%	+$1.33K	﹤0.01%	2370
2024 Q4	$2.79K	Buy	120 +9	+8%	+$264	﹤0.01%	2399
2024 Q3	$3.27K	Buy	+111	New	+$3.09K	﹤0.01%	2309
2022 Q1	–	Sell	-528	Closed	-$57K	–	2398
2021 Q4	$57K	Buy	+528	New	+$83.3K	﹤0.01%	1697

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Nisa Investment Advisors's SYRE Position: Q2 2026 in Review

Nisa Investment Advisors increased its Spyre Therapeutics (SYRE) stake by 22% in Q2 2026, buying an estimated $31.5K and bringing the position to 2,347 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #1231.

Nisa Investment Advisors first reported a position in SYRE in Q4 2021 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Nisa Investment Advisors held 2,347 shares of Spyre Therapeutics worth $208K as of Q2 2026.
Nisa Investment Advisors bought 431 Spyre Therapeutics shares in Q2 2026, an estimated $31.5K.
Spyre Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1231 holding.
Nisa Investment Advisors first reported a position in Spyre Therapeutics in Q4 2021 and has held it in 9 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.